Forma Therapeutics Stock Forecast, Price & News

+0.40 (+1.54 %)
(As of 06/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume274,741 shs
Average Volume416,644 shs
Market Capitalization$1.25 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Forma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Forma Therapeutics logo

About Forma Therapeutics

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.69 out of 5 stars

Medical Sector

324th out of 2,106 stocks

Biological Products, Except Diagnostic Industry

39th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Forma Therapeutics (NASDAQ:FMTX) Frequently Asked Questions

Is Forma Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forma Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Forma Therapeutics stock.
View analyst ratings for Forma Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Forma Therapeutics?

Wall Street analysts have given Forma Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Forma Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Forma Therapeutics?

Forma Therapeutics saw a decrease in short interest in May. As of May 28th, there was short interest totaling 2,790,000 shares, a decrease of 14.2% from the May 13th total of 3,250,000 shares. Based on an average trading volume of 400,600 shares, the days-to-cover ratio is currently 7.0 days. Currently, 7.3% of the shares of the stock are sold short.
View Forma Therapeutics' Short Interest

When is Forma Therapeutics' next earnings date?

Forma Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Forma Therapeutics

How were Forma Therapeutics' earnings last quarter?

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) released its quarterly earnings data on Thursday, May, 13th. The company reported ($0.76) EPS for the quarter, meeting analysts' consensus estimates of ($0.76).
View Forma Therapeutics' earnings history

What price target have analysts set for FMTX?

6 Wall Street analysts have issued 12 month price targets for Forma Therapeutics' shares. Their forecasts range from $54.00 to $68.00. On average, they anticipate Forma Therapeutics' stock price to reach $59.83 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price.
View analysts' price targets for Forma Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Forma Therapeutics' key executives?

Forma Therapeutics' management team includes the following people:
  • Mr. Frank D. Lee, Pres, CEO & Director (Age 53, Pay $2.42M)
  • Mr. Todd E. Shegog, Sr. VP & CFO (Age 56, Pay $706.85k)
  • Dr. Patrick F. Kelly M.D., Sr. VP & Chief Medical Officer (Age 57, Pay $655.29k)
  • Dr. John E. Bishop, Chief Technology Officer (Age 59)
  • Dr. David N. Cook, Sr. VP & Chief Scientific Officer (Age 63)
  • Dr. Jeannette Potts J.D., Ph.D., Sr. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Ms. Mary E. Wadlinger, Sr. VP of Corp. Affairs & Chief HR Officer (Age 61)
  • Mr. Andrew Littlehale MBA, Treasurer

Who are some of Forma Therapeutics' key competitors?

What other stocks do shareholders of Forma Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forma Therapeutics investors own include The Boeing (BA), Marvell Technology (MRVL), The Trade Desk (TTD), Abbott Laboratories (ABT), CVS Health (CVS), The Walt Disney (DIS), DocuSign (DOCU), Gilead Sciences (GILD), Intuit (INTU) and Neurocrine Biosciences (NBIX).

When did Forma Therapeutics IPO?

(FMTX) raised $201 million in an initial public offering on Friday, June 19th 2020. The company issued 11,800,000 shares at a price of $16.00-$18.00 per share. Jefferies' SVB Leerink and Credit Suisse acted as the underwriters for the IPO.

What is Forma Therapeutics' stock symbol?

Forma Therapeutics trades on the NASDAQ under the ticker symbol "FMTX."

Who are Forma Therapeutics' major shareholders?

Forma Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Cormorant Asset Management LP (9.96%), BlackRock Inc. (6.95%), Samsara BioCapital LLC (3.31%), Logos Global Management LP (2.98%), Janus Henderson Group PLC (1.79%) and Geode Capital Management LLC (0.91%).

Which institutional investors are selling Forma Therapeutics stock?

FMTX stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Credit Suisse AG, Citadel Advisors LLC, Russell Investments Group Ltd., Swiss National Bank, Marble Harbor Investment Counsel LLC, Bank of Montreal Can, and Chicago Partners Investment Group LLC.

Which institutional investors are buying Forma Therapeutics stock?

FMTX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Cormorant Asset Management LP, Samsara BioCapital LLC, Geode Capital Management LLC, Citigroup Inc., Northern Trust Corp, Rafferty Asset Management LLC, and Nuveen Asset Management LLC.

How do I buy shares of Forma Therapeutics?

Shares of FMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Forma Therapeutics' stock price today?

One share of FMTX stock can currently be purchased for approximately $26.36.

How much money does Forma Therapeutics make?

Forma Therapeutics has a market capitalization of $1.25 billion and generates $100.56 million in revenue each year. The company earns $-70,410,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis.

How many employees does Forma Therapeutics have?

Forma Therapeutics employs 114 workers across the globe.

What is Forma Therapeutics' official website?

The official website for Forma Therapeutics is

Where are Forma Therapeutics' headquarters?

Forma Therapeutics is headquartered at 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472.

How can I contact Forma Therapeutics?

Forma Therapeutics' mailing address is 500 ARSENAL STREET SUITE 100, WATERTOWN MA, 02472. The company can be reached via phone at 617-679-1970 or via email at [email protected]

This page was last updated on 6/25/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.